

The 3rd International Human Gene Therapy Conference	
DAY – 1 March 23, 2026	
09:00-09:45	Registrations
09:45-10:00	Welcoming Speech: Conference Co-chairs
Session 1: Technology Innovations & Gene Delivery Platforms	
10:00 – 10:20	Title: Expanding Gene Editing Beyond the Liver
	Devyn Smith, Arbor Biotechnologies, USA
10:20 – 10:40	Title: Development of Capsid- and Genome-Modified NextGen AAV Vectors; Nuclease-Free Gene Editing With AAV-B19 Hybrid and Chimeric Vectors
	Arun Srivastava, University of Florida College of Medicine, USA
10:40 – 11:00	Title: Mitigating Immune Responses to AAV Vector-Mediated Gene Transfer
	Hildegund Ertl, The Wistar Institute, USA
11:00-11:30 Coffee Break	
11:30 – 11:50	Title: TBA
	TBA
11:50 – 12:05	Title: Technology Innovations
	Jeremy Shelley ,Form BioUSA
12:05 – 12:25	Title: Gene Delivery Technologies
	Molly McGlaughlin, Revolution Biomanufacturing Inc., USA
12:25 – 12:45	Title: Gene Delivery Technologies
	Daozhan Yu, AAVnerGene, USA
12:45 – 13:05	Title: Gene Editing Therapy Development: Platform Design and Manufacturing Readiness
	Kok-Seong, Independent Consultant, USA
13:05-14:05 Lunch Break	
Session 2: Clinical Development, Trials & Therapeutic Applications	
14:05 – 14:25	Title: Isargagene Civaparovec (ST-920) Shows Positive Mean Annualized eGFR Slope in Adults With Fabry Disease: Topline Results From the Registrational Phase 1/2 STAAR Gene Therapy Study and Long-Term Follow-Up Study
	Mitra Tavakkoli,Sangamo Therapeutics , USA
14:25 – 14:45	Title: Gene Therapy for X-linked Retinitis Pigmentosa
	Daniel C. Chung, Beacon Therapeutics, USA
14:45 – 15:05	Title: Rare diseases and early phase units
	Chris A. Learn , Parexel, USA
15:05-15:25	Title: Targeting DNA Methyltransferase to Restore Vision After Traumatic Optic Nerve Injury
	Dr. Wai Lydia Tai, MEEI, Harvard Medical School, USA
15:25-16:00 Coffee Break	
16:00-16:20	Title: Genetic testing in clinical trials
	Rachel Smith, Parexel, USA
Panel Discussions	
16:20-17:00	Title: Building durable patient partnerships
	Melissa Penn, Bayer Pharmaceuticals, USA
	Daya Verma, Novartis, USA

DAY – 3 March 25, 2026	
Session 5: Manufacturing, Supply Chain & Commercialization Strategy	
10:00 – 10:20	Title: Scalable and execution-ready GT manufacturing Mihir Shukla , Biopharma Consulting Solutions, LLC , USA
10:20 – 10:40	Title: Low-cost AAV vector manufacturing Larry Forman, CHO Plus, Inc , USA
10:40– 11:00	Title: Capacity challenges & community expansion Curt Kugel, ZS, USA
11:00-11:30	Coffee Break
11:30 – 11:50	Title: A Modified CRISPR Approach Using XIST for the Treatment of Down Syndrome Brian Tomkowicz , SK pharmteco , USA
11:50 – 12:10	Title: Selective Removal of Early-Eluting Genome-Containing AAV Species with Elevated Residual DNA via Optimized Anion Exchange Chromatography Nermin Ibreljic, Sarepta Therapeutics, USA
12:10 – 12:30	Title: A Modified CRISPR Approach Using XIST for the Treatment of Down Syndrome Volney Sheen, Harvard Medical School, USA
Panel Discussions	
12:30-13:00	Title: Manufacturing and Supply Chain Strategies Michael DiBiasio-White, ViroSpark BioConsulting , USA David Greenwald , Deerfield Management,USA
13:00-13:10	Closing
13:10-14:00	Lunch Break